Table 3. Condensed chromatin area and chromatin textural contrast in 0.5 mM VPA- treated HeLa cells.
Treatment | Sc% | AAR | |||||
time (h) | Drug | X | S | Md | X | S | Md |
1 | Untreated control | 69.17 | 10.13 | 70.77a | 1.27 | 0.09 | 1.26a |
VPA | 41.30 | 21.91 | 41.76b | 1.39 | 0.16 | 1.36b | |
2 | Untreated control | 68.53 | 14.52 | 70.65a | 1.25 | 0.08 | 1.24a |
VPA | 30.51 | 20.73 | 31.11b | 1.44 | 0.15 | 1.43b | |
4 | Untreated control | 60.15 | 13.17 | 60.86a | 1.36 | 0.14 | 1.35a |
VPA | 49.52 | 21.42 | 56.41b | 1.39 | 0.15 | 1.38a | |
24 | Untreated control | 57.75 | 14.84 | 59.91a | 1.35 | 0.14 | 1.32a |
VPA | 42.31 | 22.42 | 47.41b | 1.38 | 0.15 | 1.34a |
, The median values of the VPA groups and their respective control for each treatment time differ significantly from each at the P 0.05 level (Mann-Whitney test); AAR, average absorption ratio; Md, median; S, standard deviation; Sc %, relative condensed chromatin area; VPA, valproic acid; X, arithmetic mean; n, 200